Jul 22, 2009
By:
Jill Wechsler
Collins seeks to parlay genomic discoveries into new biomedical therapies. Comparative effectiveness research, he says, should identify subpopulation responses to treatment and support personalized medicine.
|
Jul 1, 2009
By:
Jill Wechsler
As FDA looks to balance risks and benefits, more regulations are on the horizon.
|
Jun 1, 2009
By:
Jill Wechsler
FDA is seeking more resources to support compliance and oversight.
|
May 21, 2009
By:
Jill Wechsler
Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.
|
May 1, 2009
By:
Jill Wechsler
Pharma fears comparative effectiveness research will focus on costs and stymie personalized medicine.
|
Apr 1, 2009
By:
Jill Wechsler
In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
|
Mar 1, 2009
By:
Jill Wechsler
The latest buzzword in pharma is "transparency"
|
Feb 1, 2009
By:
Jill Wechsler
A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths.
|
Jan 1, 2009
By:
Jill Wechsler
Will more resourches and new leadership fix FDA, or is a major overhaul in order?
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
